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Purpose. The most common pharmacological therapies used in the treatment of stridor in children are glucocorticosteroids (GC)
and alpha-adrenergic (αAR) agonists. Despite the long-standing reported eﬃcacy of these medications, there is a paucity of data
relating to their actual mechanisms of action in the upper airway. Summary. There is compelling scientiﬁc evidence supporting the
use of αAR-agonists and GCs in pediatric stridor. αAR signaling and GCs regulate the vasomotor tone in the upper airway mucosa.
The latter translates into better airﬂow dynamics, as delineated by human and nonhuman upper airway physiological models. In
turn, clinical trials have demonstrated that GCs and the nonselective αAR agonist, epinephrine, improve respiratory distress scores
and reduce the need for further medical care in children with stridor. Future research is needed to investigate the role of selective
αAR agonists and the potential synergism of GCs and αAR-signaling in the treatment of upper airway obstruction and stridor.
1.Introduction
Stridor is a common presenting symptom in children, and
its treatment must be tailored according to its underlying
condition. Even though there are many disorders that can
induce stridor, they often share a common pathophysiology
producing dynamic collapse of the extrathoracic airway
during inspiration [1, 2]. This resultant inspiratory ﬂow
limitation may be associated with a range of impairment,
producing increasing breathing eﬀorts and distress. When
surgicalcorrectionisnotindicated,forinstancewhenstridor
is caused by viral croup or occurs immediately after extuba-
tion, pharmacological agents are primarily used. The main
goal of pharmacological therapy for stridor is to alleviate,
or prevent, upper airway collapse during inspiration by
optimizing intraluminal patency and airway wall stability.
The most common pharmacological therapies used in chil-
dren are glucocorticosteroids (GC) and alpha-adrenergic
(αAR)agonists,particularlydexamethasoneandinhaledepi-
nephrine, respectively [3]. Despite the long-standing report-
ed eﬃcacy of these medications, there is a paucity of data
describing their actual mechanisms of action in pediatric
stridor. This article aims to review the current knowledge
of the physiological activity of αAR agonists and GCs in the
upper airway, as well as the potential synergistic eﬀect of
their combined administration. Also reviewed is the current
clinical evidence describing the safety and eﬃcacy of these
medications for the treatment of stridor in children.
2.Alpha-Adrenergic(αAR)Agonists and
the Regulation of the Vasomotor Tone of
the Upper Airway
2.1. Molecular and Cellular Eﬀects of αAR Signaling in the
Upper Airway. Alpha-adrenoreceptor (αAR) signaling has a
signiﬁcantregulatoryroleinmaintainingthevasomotortone
of the upper airway [4–8]. The α1a n dα2 AR are located in
the smooth muscle (SM) of the nasal cavernous bodies and
the vascular framework of the mucosa that covers the entire
upper airway [4–13]. The stimulation of these receptors
enhances SM contractile tone, which in turn increases nasal2 International Journal of Otolaryngology
Table 1: Molecular and cellular eﬀects of αAR-agonists and glucocorticoids in the upper airway.
Treatment modality Physiological eﬀects
αAR-agonists
(i) Increased vascular smooth muscle (VSM) contractile tone
Gq protein-mediated VSM contraction (α1)
Gi protein-mediated VSM impaired relaxation (α2)
(ii) Modulation of mucosa blood ﬂow and thickness
(iii) Increased nasal cavity cross-sectional area
(iv) Increased oropharyngeal patency
(v) Increased subglottic intraluminal diameter
Glucocorticoids
(i) Transrepression of AP-1 and NF-κB transcription factors
(ii) Regulation of mitogen-activated protein kinases (MAPKs)
(iii) Modulation of vascular endothelial growth factor (VEGF) expression
(iv) Enhanced αAR-signaling and prevention of αAR-homologous desensitization
(v) Modulation of airway mucosa inﬂammation
(vi) Reduced airway mucosa thickness
(vii) Increased nasal and subglottic patency
[4, 8] and oropharyngeal patency [5, 6]. The primary
cellular mechanism elicited by αAR-stimulation in SM is
G-protein coupled receptor-(GPCR-) mediated activation
of intracellular cascades that upregulate calcium-mediated
SM contraction [14, 15] and ameliorate cAMP-induced SM
relaxation [13, 16]. The physiological result of this αAR-
induced SM contractile tone is a decreased thickness of the
mucosa and other soft tissue layers, thereby increasing the
intraluminal space of the upper airway. In this regard, the
thickness of the mucosa in the airway is largely determined
by (1) blood ﬂow regulated by the mucosal vascular tone and
(2) interstitial ﬂuid collection, or edema, which is the end-
product of an imbalance between interstitial-oncotic forces,
vascularpermeability,andlymphaticeﬄux[17,18].Wasicko
et al. demonstrated that αAR-agonists exert their primary
eﬀect in the upper airway mucosal mass by regulating
the intravascular blood ﬂow [5]. This was supported by
magnetic resonance imaging (MRI) of the upper airway of
animal models that showed immediate changes in the upper
airway mucosal size and tissue water content in response
to the infusion with the αAR-agonist vasoconstrictive agent
phenylephrine [5]. These changes were completely reversed
by the vasodilating agent sodium nitroprusside, which led
the authors to conclude that the αAR-induced changes in
mucosal size are unlikely to be caused by variations in
the interstitial ﬂuid volume. The later ﬁndings are fur-
ther substantiated by experiments demonstrating rapid and
reversible ﬂuctuations in the presence of the intravascular
contrast agent Gd-DTPA in the upper airway mucosa follow-
ing phenylephrine and sodium nitroprusside administration
[5]. In addition, topical administration of αAR-agonists
induces rapid and dramatic changes in the size of the nasal
mucosa [6, 8, 19] and oropharyngeal mucosa of human
subjects [6]. Taken together, the clinical implication of these
ﬁndings is that the pharmacological action of αAR-agonists
involves a profound eﬀect in the mucosal size (vascular tone)
and airway patency (Table 1), but that this therapy does not
target the underlying disease mechanism in many instances,
such as with airway edema. Thus, the beneﬁcial eﬀects of
αAR-agonists on mucosal mass size and airﬂow dynamics are
likely to be transient.
2.2. αAR-Agonist Mediated Eﬀects in Nasal and Oropharyn-
geal Airﬂow Dynamics. The previously described cellular
and molecular eﬀects of αAR-stimulation in upper airway
mucosa have raised an important question: do these changes
in the airway mucosal size and patency translate into
beneﬁcial mechanical changes in airway wall collapsibility
and airﬂow? This concept is important because the majority
of pediatric conditions associated with stridor and upper
airway obstruction are characterized by dynamic inspiratory
collapse of the upper airway [1–3]. Indeed, there is com-
pelling evidence demonstrating that αAR-agonists enhance
both nasal cavity cross-sectional area and nasal airﬂow,
assessedbyacousticrhinometry(AR)[19,20]andpeaknasal
inspiratory ﬂow (PNIF), respectively [21]. Interestingly,
Kjaergaard et al. have recently reported that changes in nasal
cavity geometry induced by αAR-agonists directly correlates
with increased nasal airﬂow in a linear fashion [22]. This
ﬁnding is probably explained by the active action of the alae
nasi muscles that help prevent nasal collapse even under
conditions of maximal nasal inspiratory ﬂow [23].
αAR-agonists also improve airﬂow mechanics in the
oropharyngeal airway. Experiments using in vivo animal
models of sealed upper airways have demonstrated that the
closing and opening pressures of the oropharynx are tran-
siently modiﬁed by the administration of phenylephrine
[5]. In addition, topical oropharyngeal phenylephrine use
in humans causes decreased airﬂow resistance independently
of changes in nasal resistance or upper airway muscle tone
[6]. These eﬀects of αAR-signaling in the regulation of
oropharyngeal airﬂow and collapsibility are attributed to
the preferential action of αAR-agonists in the posterolateral
mucosa of the oropharynx [5], an area prone to collapse
under conditions of upper airway obstruction [24, 25]. In
conclusion, the pharmacological eﬀects of αAR-agonists inInternational Journal of Otolaryngology 3
Table 2: Eﬀects of αAR-agonists and glucocorticoids in upper airway breathing mechanics.
Treatment modality Physiological eﬀects
αAR-agonists
(i) Increased nasal inspiratory ﬂow (PNIF)
(ii) Decreased oropharyngeal resistance and collapsibility
(iii) Decreased total respiratory resistance (RT)
(iv) Decreased inspiratory and expiratory resistance (RAW0.5I and RAW0.5E)
(v) Decreased work of breathing (WOB)
(vi) Paradoxical nasal obstruction (vasomotor rebound)
(vii) Rebound increase in total respiratory resistance (RT)
Glucocorticoids
(i) Increased nasal inspiratory ﬂow (PNIF)
(ii) Decreased nasal airway resistance (NAR)
(iii) Increased nasal volume by acoustic rhinometry (AR)
(iv) αAR-induced vasomotor rebound prevention (changes in PNIF, AR and NAR)
the treatment of stridor and upper airway obstruction seem
to be related to their regulatory role and increasing vasomo-
tor tone of the nasal and posterolateral oropharyngeal airway
mucosa. The consequent eﬀects of this increased vasomotor
tone are likely changes in the mechanical properties of the
upper airway resulting in less collapsibility, less resistance,
a n di m p r o v e da i r ﬂ o w( T a b l e2).
3. Glucocorticosteroid (GC)Effects on
the Upper Airway Function
3.1.MolecularandCellularEﬀectsofGCSignaling. Glucocor-
ticosteroids (GCs) are hormones with a ubiquitous intracel-
lular receptor (GR) and a broad range of biological actions
in diﬀerent body cells and systems. The primary cellular
mechanism elicited by GR-activation is the stimulation of
the GC response elements (GREs) in the promoter region
of primary or secondary genes [26]. The GRE complexes
modulate transcription factors such as NF-κBo rA P - 1w h i c h
are considered critical for many proinﬂammatory signals
[26, 27]. Additional mechanisms include the regulation of
intracellular mitogen-activated protein kinases (MAPKs)
[28–30] and nongenomic GC-mediated actions that include
the regulation of second messengers and ion channels [31].
The most common therapeutic use of GCs is the attenuation
of inﬂammation and immune responses via GR activation
in T-cell lymphocytes and other immune cells [26, 32, 33].
However, GCs are also known to modulate the function of
multiple components in the respiratory system including
cells in the epithelium [34, 35]a sw e l la ss m o o t hm u s c l e
in the airways [29, 34, 36, 37] and blood vessels [38, 39].
Accordingly, GCs appear to exert their action in the upper
airwaythroughtheregulationofseveralprocessesindiﬀerent
cell lines.
3.2. Genomic and Nongenomic Mechanisms of Action of GC
in the Upper Airway. GCs typically exert rapid, delayed, and
long-term eﬀects in the upper airway [40]. Long-term eﬀects
are likely due to GRE-mediated antiinﬂammatory action and
suppressed microvascular permeability yielding less mucosal
edemaformation[40].Thereiscompellingevidencedemon-
strating that topical GC in patients with allergic rhinitis
and other types of upper airway inﬂammation signiﬁcantly
reduces the local release of multiple cytokines and vasoactive
inﬂammatory mediators [40–43], and also lessens cellular
inﬁltration in the respiratory mucosa [44]. Moreover, GCs
modulate the expression of vascular endothelial growth
factor (VEGF), which is a crucial angiogenesis stimulator
that induces vascular permeability and vasodilatation via
nitrogen oxide (NO) synthesis by the endothelium [45, 46].
In addition to GRE-mediated genomic mechanisms,
therearealsonongenomicactionsofGCsthatcanpotentially
mediate more rapid eﬀects of GC in upper airway function.
For instance, GCs inhibit the synthesis of arachidonic acid
derivatives that aﬀect vascular permeability and tone (i.e.,
prostaglandins) [47]. GCs also aﬀect the vascular smooth
muscle tone by directly regulating intracellular levels of
calcium and relaxant cyclic nucleotides (cAMP and cGMP)
[29, 48] and indirectly enhancing αAR-mediated signaling
[49]. Another nongenomic action of GC is the regulation of
Cl-ion channels and Na+/H+ exchange in respiratory epithe-
lial cells, which induces an immediate decrease in net water
eﬄux [50–52]. As a result, nongenomic eﬀects of GCs can
potentially induce rapid volume changes in the intravascular
andinterstitialcompartmentsoftheairwaymucosareducing
the thickness of the airway wall [53–55].
These cellular and molecular mechanisms of GC action
translate in a reduction of upper airway ﬂow obstruction
and stridor [56, 57] with a delayed peak of clinical eﬀect of
approximately 6 hours after their initial administration [57].
Taken together, this evidence suggests that a combination of
genomic and nongenomic actions of GCs is necessary for
the full pharmacological activity of GCs on upper airﬂow
dynamics (Tables 1 and 2).
4. Molecular Interactionsof αAR Agonists and
GC inthe Upper Airway:Modulating α-AR
Homologous Desensitization
4.1. αAR Agonists-Induced Homologous Desensitization in the
Upper Airway. Although αAR agonists acutely relieve upper
airway obstruction [58], their chronic use induces desen-
sitization to the αAR-mediated eﬀect (tachyphylaxis) and4 International Journal of Otolaryngology
paradoxical rebound obstruction [59–62]. This is supported
by the increased upper airway resistance observed in healthy
subjects who have received prolonged αAR-agonist admin-
istration [59]. In addition, chronic nasal administration of
nonselective α1/α2 agonists (i.e., oxymetazoline) induces
rhinitis medicamentosa, a condition characterized by re-
bound nasal congestion and pathologic changes in the vas-
culature of the nasal mucosal [63]. This rebound eﬀect
observed following sustained αAR-stimulation can also oc-
cur after administration of other αAR agonists utilized in the
therapy of upper airway obstruction and stridor [64]. This
paradoxical eﬀect of αAR-signaling is termed homologous
desensitization, and it is observed following prolonged stim-
ulation of all types of α and β adrenoreceptors [65–67]a n d
other G-protein coupled receptors [68]. There are several
molecular mechanisms that may explain this desensitization,
including internalization and uncoupling of the surface AR
[51] and modulation of the AR-coupled intracellular signal-
ingpathwaysthatregulatesecondmessengers(suchascAMP,
cGMP, IP3, and calcium) [65–68]. This phenomenon of
AR-induced paradoxical rebound obstruction raises serious
safety concerns regarding the sole use of these types of med-
ications for the treatment of numerous upper airway condi-
tions [69].
4.2. Beneﬁcial Eﬀects of GC in αAR Signaling and Homol-
ogous Desensitization. GCs prevent the generation of AR-
homologousdesensitizationindiﬀerentcelllines[29,70,71].
They increase the cell surface αAR and βAR numbers in
the respiratory system [49, 72]a sw e l la su p r e g u l a t eA R
downstream signaling by modulating activation of protein
kinases,includingtheMAPKs,ERK1/2,P38,andc-JunNH2-
terminal kinase (JNK) [29, 73] .A sar e s u l t ,G C se x e r tas y n -
ergistic action on AR agonist therapy for numerous airway
diseases [74]. In the upper airway, GCs modulate the eﬀects
of αAR-agonists on the airway vasomotor tone, thereby
improving airﬂow dynamics [56]. Topical GCs even reduce
upper airway mucosal size in individuals with nonallergic
vasomotor rhinitis [75–77] and prevent the development
of αAR-agonist-induced tachyphylaxis [78]. Furthermore,
recent randomized clinical studies have suggested that the
combination of GC and αAR-agonists together provide a
synergistic eﬀect in the treatment of nasal [78, 79]a n dm o r e
distal airway obstruction [80]. This evidence underscores
the importance of the nonimmune-mediated mechanisms of
action of GC in the regulation of the vasomotor tone and
upper airway function.
In concert with the beneﬁcial eﬀects of GCs in αAR-
signaling, the use of nonselective αAR agonists with βAR
activity for the treatment of stridor (i.e., epinephrine) may
lead to enhanced GC signaling via β2-AR-induced upregu-
lation of GRE-dependent transcription [81]. In this regard,
prior investigations have demonstrated that the addition
of long-acting β2-AR agonists to GC therapy results in
upexpression of various antiinﬂammatory proteins such as
GC-inducible leucine zipper (GILZ) and MKP-1 to an extent
not achievable by exposure to GC alone [81]. The latter
evidence suggests that the antiinﬂammatory action of GCs in
the upper airway might be potentially augmented by simul-
taneous administration of nonselective AR-agonists with β-
AR activity such as epinephrine; however, this possibility
remains to be systematically investigated.
In summary, there are several molecular interactions
between αAR and GC signaling that inﬂuence upper airway
ﬂow dynamics (Figure 1). These positive interactions poten-
tially provide a physiological rationale for the combined use
of αAR-agonist and GCs in the therapy of upper airway
obstruction and stridor.
5. Clinical Evidenceof the Use of α-AR Agonists
andGCintheTreatmentofPediatricStridor
Clinical conditions that produce new onset stridor in chil-
dren are typically associated with increased mucosal thick-
ness and resultant intraluminal narrowing of the extratho-
racic airway (nose, pharynx, larynx, and trachea). There
are two major mechanisms of disease causing upper airway
mucosa swelling in children: (1) infectious/inﬂammatory
related, most commonly associated with viral laryngotra-
cheobronchitis, or “croup” and (2) mechanical trauma,m o s t
often related to endotracheal intubation and foreign bodies
in the upper airway. The clinical evidence supporting the
eﬃcacy of αAR agonists and GCs in the treatment of both
these types of stridor-causing mechanisms in children is
discussed next.
5.1. Role of αAR-Agonists in the Treatment of Viral-Induced
Stridor. Randomized controlled trials (RCTs) have consis-
tently demonstrated that the nebulized use of the nonselec-
tiveαAR-agonist andβAR-agonist, epinephrine, signiﬁcantly
relieves the distressing symptoms of croup in young children
[82–87].Indeed,theeﬀectivenessofepinephrineinthetreat-
ment of stridor associated with croup has been extensively
studied in pediatric age group since the 1970s [82–85].
Many initial studies demonstrated signiﬁcant improvements
in croup symptom scores compared to placebo at 10 and
30 minutes after administration, with waning eﬀects by 120
minutes after treatment [82–87]. In addition to changes
in clinical scores, inhaled epinephrine signiﬁcantly reduces
tracheal diameter [88], and improves breathing mechanics
[89] in children with stridor from viral croup.
Most initial clinical trials studying pediatric stridor
focused on the eﬃcacy of treatment with the racemic form
of epinephrine, which contains dextro (R) and levo (L)
isomers. Waisman et al. then established that nebulized
isomeric (L) epinephrine, which is more widely available
than the racemic form, is equally eﬀective for the treatment
of viral croup in children [86]. In addition, although in-
haled epinephrine is the only αAR-agonist therapy with
suﬃcient clinical evidence to support its use in pediatric
viral-induced stridor [87], there is data suggesting that other
αAR-agonists could be eﬃcacious [64]. This knowledge is
important because epinephrine, which is a catecholamine
with nonselective αAR and βAR agonist properties, has
signiﬁcant cardiovascular side eﬀects related to its poor
receptor speciﬁcity [90]. In this regard, Lenney and Mil-
ner reported that a single inhalation with phenylephrineInternational Journal of Otolaryngology 5
• Primarily αAR control
• GCs modulate vasoresponsiveness
(αAR desensitization and rebound)
1. Blood ﬂow regulation
• Primarily genomic and nongenomic
GC actions
2. Interstitial ﬂuid and cellular
inﬁltration
The mucosal mass size modulates the
patency and collapsibility of the upper airway
Upper airway mucosa
Figure 1: Regulatory eﬀects of alpha-adrenoreceptor-(αAR-) agonists and glucocorticoids (GCs) in the upper airway mucosa.
(a selective αAR-agonist) in a small cohort of young children
with viral croup, produced transient clinical improvement
of stridor and decreased respiratory resistance, measured by
modiﬁed forced oscillation [64]. Moreover, a recent RCT
demonstrated that the nasal administration of the pure αAR-
agonist, xylometazoline, was equally eﬀective compared to
nebulized epinephrine in decreasing respiratory distress in
the setting of a viral respiratory illness [91]. These ﬁndings
are consistent with the prevailing concept that the adrenergic
control of the upper airway is largely mediated by αAR-
signaling[4–13],anditsuggeststhattheeﬀectofepinephrine
in reducing viral-induced stridor is most likely mediated by
its αAR-properties. Nevertheless, there remains insuﬃcient
evidencetosupporttheroutineuseofalternateαAR-agonists
for the treatment of viral-induced stridor in children.
The eﬃcacy of nebulized epinephrine has recently been
highlighted in a Cochrane review that evaluated its use for
viral-induced croup in children [87]. This review included
8 RCTs or quasi-RCTs with a total pool of 225 children
diagnosed with croup in the ER or inpatient hospital setting.
The primary outcome of these studies was croup score after
treatment with nebulized epinephrine. Secondary outcomes
included duration of intubation, length of hospitalization,
number of return visits for croup, parental anxiety level, and
medication side eﬀects. The authors concluded that the use
of nebulized epinephrine, either as racemic or L-isomeric
preparation, is signiﬁcantly associated with transient reduc-
tion of croup symptoms 30 minutes after treatment [87].
Takentogether, thecurrent clinical evidencesupports the use
of nebulized epinephrine as the ﬁrst-line rescue therapy for
children presenting with stridor and croup-related respira-
tory distress elicited by acute viral laryngotracheobronchitis
(Table 3).
5.2. GCs and the Treatment of Viral Croup in Children. GCs
are considered the mainstay of therapy for viral croup in
children [3, 92]. As previously described, GCs reduce upper
airway swelling which leads to signiﬁcant improvement in
croup symptoms. Their onset of action is about an hour
after administration, which is delayed compared to that of
inhaled epinephrine, and their peak eﬀect is noted 6–12
hours after administration [57, 93] .G C sh a v eb e e nu s e di n
the treatment of children presenting to an ER with stridor
caused by viral-induced croup in children for many years,
and their eﬃcacy has been extensively studied using multiple
administration routes. A seminal RCT conducted by Bjorn-
son et al. [92] evaluated the eﬃcacy of oral dexamethasone
in 720 children with mild croup (croup score ≤2 on the
Westley croup scoring system). They found that a single dose
of oral dexamethasone (0.6mg/kg/dose, maximum 20mg)
resulted in a signiﬁcantly quicker resolution of symptoms
and improvement in croup score compared to placebo [92].
AdditionalstudieshaveconsistentlyshownthatGCsimprove
croup symptoms scores and reduce hospital admissions [57,
92–94]. In addition, a recent cochrane review of 38 RCTs,
with a total of 4299 children pooled, further conﬁrmed that
GCs are eﬀective in improving croup score symptoms and
decreasing the number of return visits, (re)admissions, and
hospital length of stay [57].
Multiple studies have investigated diﬀerent routes, doses,
and types of GCs in order to identify their optimal use in6 International Journal of Otolaryngology
Table 3: Clinical eﬀects of αAR-agonists and glucocorticoids in viral-induced stridor.
Treatment modality Clinical outcomes
αAR-agonists (i) Transient improvements in croup symptom scores compared to placebo at 10
and 30 minutes after administration (duration 120 minutes)
(i) Nebulized racemic epinephrine
(ii) Nebulized (L) isomeric epinephrine (ii) Shorter hospital stay
Glucocorticoids
(i) Dexamethasone (0.15–0.6mg/kg)∗ (i) Signiﬁcant improvement in croup symptom scores, starting about an hour
after administration
(ii) Nebulized budesonide (2–4mg) (ii) Sustained eﬀe c ti nc r o u ps y m p t o ms c o r e s( p e a k6 –12 hours after
administration)
(iii) Betamethasone (0.4mg/kg/dose) (iii) Decreased number of return visits or (re)admissions
(iv) Prednisolone (1mg/kg/dose) (iv) Decreased length of time spent in the hospital
∗The majority of large randomized clinical trials have been conducted with dexamethasone, but there is clinical evidence suggesting equivalent responses with
other glucocorticoids used in viral-induced stridor.
the management of viral croup in children. Oral dexametha-
sone (0.6mg/kg/dose) has been found to be as eﬀective as
intramuscular dexamethasone [94], and both are superior
to nebulized dexamethasone in the treatment of mild and
moderately severe croup in children [95]. Interestingly, high-
dose nebulized budesonide (2–4mg) seems to be equally
eﬀective as either oral or intramuscular dexamethasone in
treatment of croup [96–98]. Nebulized budesonide may
also play a role as adjunct therapy to dexamethasone in
the management of mild-moderate croup in the outpatient
setting [99] ,b u ti td o e sn o ta d db e n e ﬁ ti nt h et r e a t m e n t
of children hospitalized with croup [100]. Conversely, the
administration of high-dose ﬂuticasone (2,000 micrograms)
via metered dose inhaler (MDI) and spacer did not provide
any clinical beneﬁt in children with viral croup in a small
RCT with 17 patients [101]. This might suggest that the
correct use of MDI inhalers results in much less medication
deposition in the upper airway and these devices may not
be indicated for the treatment of stridor. With regards to
alternate dosing, oral dexamethasone dosed at 0.15mg/kg
may be equally eﬀective as dosing at 0.6mg/kg for the
treatment of moderate to severe croup [102–105]. Regarding
the use of diﬀerent classes of GCs, oral betamethasone
(0.4mg/kg/dose) seems as eﬃc a c i o u sa so r a ld e x a m e t h a s o n e
(0.6mg/kg/dose) in children with mild to moderate croup
[106]. Oral prednisolone (1mg/kg/dose) also improves
croup clinical scores [104, 107], but it may be less eﬀective
thandexamethasone in reducing thenumber ofunscheduled
representationstomedicalcare[107].However,arecentRCT
did not observe signiﬁcant diﬀerences between the use of
prednisolone (1mg/kg/dose) and dexamethasone (dosed at
either 0.15 or 0.6mg/kg) in the treatment of children with
mild to moderate croup [104].
In summary, there is compelling evidence demonstrating
the eﬀectiveness of using GCs in the treatment of viral-
induced stridor in the pediatric population (Table 3). Multi-
pleRCTsstudyingchildrenwithviralcrouphaveconsistently
shown signiﬁcant improvement of clinical scores, less return
visits,andshorterhospitalstayfollowingGCadministration.
Oral, parenteral and nebulized GCs (but not via MDI with
spacer) appear to provide similar clinical beneﬁts. There
are no major diﬀerences in clinical response when using
alternate routes of GC administration, but the inhaled route
may need high-doses to have comparable eﬀects. Given
that the vast majority of the pediatric clinical evidence
currently available relates to the use of dexamethasone (dose
0.15mg/kg to 0.6mg/kg), this GC is most recommended for
the treatment of viral-induced stridor in children.
5.3. Trauma-Related Stridor in Children: αAR-Agonists and
GCs in the Postextubation Period. Post-extubation stridor
is seen uncommonly in adults, but it often occurs in
young children under 5 years of age, with a reported
incidence of 1–4% [108]. The pathophysiology of this
condition involves local mucosal and submucosal trauma
caused by the endotracheal tube with resultant transient
intraluminal subglottic narrowing due to airway edema
[109]. Initially, the role of αAR-agonists and GCs in this
condition was investigated utilizing in vivo animal models
of trauma-induced stridor [109]. In these experiments, a
ferret model of postintubation croup was used to illustrate
thatboththetopicalapplicationoftheselectiveαAR-agonist,
oxymetazoline, and the intramuscular administration of
dexamethasone completely ablated the subglottic edema
induced by traumatic intubation [109]. Subsequent studies
have further supported the use of these therapies for the
managementofpostextubationstridorinadultsandchildren
[110–119]. In concordance with the beneﬁcial eﬀects of
nebulized epinephrine and dexamethasone in the treatment
of stridor from viral croup [87], most clinical studies have
focused on evaluating the eﬀectiveness of these medications
in the prevention and treatment of postextubation stridor.
Racemic epinephrine and L-epinephrine have been
showninRCTstoimproveclinicalscoresinpediatricpatients
who developed stridor in the immediate postextubation
period [110]. As expected, this αAR-mediated eﬀect is short
lasting [110], which mandates the need for alternative or
coadjuvant therapies. Accordingly, the eﬃcacy of GCs in
the prevention of postextubation stridor has also been
extensively studied, especially when comparing them to the
use of αAR-agonists alone. Among high-risk neonates with
a history of traumatic, multiple, or prolonged intubation,International Journal of Otolaryngology 7
Table 4: Clinical eﬀects of αAR-agonists and glucocorticoids in postextubation stridor.
Treatment modality Clinical outcomes
αAR-agonists:
(i) Nebulized racemic epinephrine
(ii) Nebulized (L) isomeric epinephrine
(i) Transient improvements in croup symptom scores compared to placebo at 10
and 30 minutes after administration (duration 120 minutes)
Glucocorticoids (i) Reduced rates of postextubation stridor in adults and certain pediatric groups
(i.e., high-risk patients)
(i) Dexamethasone (0.15–0.6mg/kg) (ii) Probable decrease in reintubation rates in select cases, but not in general adult
and pediatric populations
the use of either one or three doses of intravenous (i.v.)
dexamethasone (0.25mg/kg/dose) resulted in fewer patients
with postextubation stridor and fewer patients requiring
reintubation [111, 112]. Similar ﬁndings have been reported
when treating pediatric patients outside of the neonatal
period. A prospective RCT of children less than 5 years of
age, who were intubated and mechanically ventilated for >48
hrs, reported that IV dexamethasone (0.5mg/kg/dose 6–12
hours before the extubation and then every 6 hours for a
total of 6 doses) was associated with lower croup scores,
less frequency of stridor, and fewer episodes of reintubation
and/or acute treatment with nebulized epinephrine [113].
Prednisolone (1mg/kg/dose) has also been identiﬁed to
reduce the duration of intubation and the need for rein-
tubation in children >6 months old intubated for croup
[114]. However, a separate RCT showed no beneﬁt of
GC in preventing reintubation following an initial “failed”
extubation due to stridor [120]. Importantly, children that
requiredreintubationinthisstudyhadsigniﬁcantneurologic
impairment, which correlated closely with reintubation rates
[120]. Recently, the utility of GC in the treatment of
postintubation stridor has been summarized in a cochrane
review of 11 RCTs (2 neonatal RCTs and 3 RTCs in older
children) that pooled a total of 2301 patients, adult and
pediatric combined. The authors concluded that while there
is insuﬃcient evidence supporting routine GC use for the
prevention of postextubation stridor in children, there is
a consistent trend towards reduced rates of reintubation
and postextubation stridor, particularly among high-risk
patients [121]. Of note, the analysis also identiﬁed that
GC signiﬁcantly reduced postextubation stridor in adults,
although GC-induced eﬀect on reintubation rates did not
reach statistical signiﬁcance [121].
In summary, there is compelling evidence demonstrating
beneﬁcial eﬀects of using both nebulized epinephrine and
systemic GC to reduce the upper airway intraluminal nar-
rowing induced by endotracheal intubation (Table 4). These
data are consistent with previous clinical studies that estab-
lished the eﬃcacy of αAR-agonists and GCs in treating
stridor during acute viral laryngotracheobronchitis [57,
87]. Notwithstanding this evidence, the clinical usefulness
of these therapies at improving critical outcomes (i.e.,
reintubation rates) requires further investigation, especially
because these eﬀects have not yet been observed in all
groups of pediatric patients. Thus, GC use during the
postextubation period requires careful evaluation of the
underlying disorder and associated comorbidities in neona-
tal and pediatric patients.
5.4. Safety of αA R - A g o n i s t sa n dG C sd u r i n gt h eT h e r a p yo f
Stridor in Children. The known potential adverse eﬀects of
αAR-agonists and GC administration in children requires
consideration. GCs use predisposes to many systemic side
eﬀects including hyperglycemia, decreased bone density,
altered hypothalamic-pituitary-adrenal axis, and abnormal
immuneresponses[122].Speciﬁctothepediatricpopulation
is the potential decreased rate of growth [123] associated
with the prolonged use of systemic GCs and high-doses of
inhaled GCs [124]. A speciﬁc concern regarding the use
of GC in viral-induced croup is the potential generation
of severe bacterial [125] or fungal laryngotracheitis [126],
which are reported complications in this setting. With
regards to αAR-agonists, nebulized racemic epinephrine
has been associated with potential serious cardiovascular
complications in children treated for viral croup [90]. These
eﬀects are related to its nonselective αAR and βAR actions,
and their action may induce tachycardia, hypertension, and
myocardial infarction [90]. Despite these potential serious
complications, the vast majority of clinical studies have
demonstrated that both GCs and nebulized epinephrine
are well tolerated without serious complications consistently
reported during the therapy of pediatric stridor [57, 87].
5.5. Potential Clinical Synergism of αAR-Agonists and GCs
in Pediatric Stridor. As previously mentioned, tachyphylaxis
and rebound may be deleterious consequential eﬀects of
αAR-agonists. The latter side eﬀects are present in the nasal
mucosa [59–62] and more distal segments of the upper
airway [64]. These changes in αAR function are attributed
to AR-homologous desensitization, which is modulated by
GC signaling [29]. This molecular mechanism provides
the basic foundation for the potential synergistic use of
combined GC and αAR-agonist therapy. Two recent RCTs
have demonstrated that GCs actually prevent αAR-agonist
induced tachyphylaxis and rebound in the treatment of nasal
congestion [78, 79]. The beneﬁcial eﬀects of the combined
use of GCs and nebulized epinephrine in the treatment of
respiratory distress associated with acute viral illnesses in
childrenhavealsobeenreported[80].Althoughthesestudies
areoftenaimedtoassessspeciﬁcrespiratorysyndromes,such
as viral croup or viral bronchiolitis, the eﬀect of nebulized8 International Journal of Otolaryngology
epinephrine is likely due to its αAR-agonist action in the
upper airway, regardless of underlying syndrome [91]. The
synergy of the use of GCs and nebulized epinephrine was
supported by a recent multicenter RCT involving 800 infants
with viral bronchiolitis [80]. They convincingly demon-
strated that the combined use of dexamethasone and nebu-
lizedepinephrineprovidedasigniﬁcantreductioninhospital
admission rate and improved clinical respiratory distress
scores superior to either therapy alone [80]. This seminal
RCT suggests a signiﬁcant synergism between epinephrine
and dexamethasone, particularly because dexamethasone
alone has not been associated with signiﬁcant clinical beneﬁt
in viral bronchiolitis, as demonstrated by several RCTs [127,
128]. In the setting of viral-induced croup, the addition
of dexamethasone to epinephrine prevents relapses and
hospital admissions [129], as well as improves croup scores
[130–132]. Nonetheless, until clinical evidence from RCTs
speciﬁcally designed to investigate the synergism of αAR-
agonist and GCs in pediatric stridor is available, combined
therapy is not currently recommended for the routine
treatment of stridor in children.
6. Conclusions andFutureDirections
There is compelling scientiﬁc evidence supporting the use
of alpha-adrenergic (αAR) agonists and glucocorticosteroids
(GCs)inthetreatmentofpediatric upperairwayobstruction
andstridor. Atthe“bench”level,itisclearthattheregulation
of the vasomotor tone and extravascular volume in the
upper airway mucosa is the result of complex mechanisms
and interactions between αAR signaling and genomic and
nongenomic GC eﬀects. The latter molecular and cellular
events translate into better airﬂow mechanics, as observed
in several human and nonhuman upper airway physiological
models. When tested in the clinical arena, αAR-agonists and
GCs hold their beneﬁcial eﬀects in upper airway function.
Several randomized controlled trials (RCTs) have consis-
tently demonstrated that GC and αAR-agonists, particularly
dexamethasone and nebulized epinephrine, improve respi-
ratory distress scores and reduce need for further medical
care in children with viral-induced croup or traumatic
postextubation stridor. Future research directions should
include clinical and translational studies that investigate the
potential beneﬁts of selective αAR-agonists and combined
therapy (GC and αAR-agonists) in the treatment of upper
airway obstruction and stridor in neonates, infants, and
children.
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